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Abstract
Robustness, a long-recognized property of living systems, allows function in the face of uncertainty while fragility, i.e.,
extreme sensitivity, can potentially lead to catastrophic failure following seemingly innocuous perturbations. Carlson and
Doyle hypothesized that highly-evolved networks, e.g., those involved in cell-cycle regulation, can be resistant to some
perturbations while highly sensitive to others. The ‘‘robust yet fragile’’ duality of networks has been termed Highly
Optimized Tolerance (HOT) and has been the basis of new lines of inquiry in computational and experimental biology. In
this study, we tested the working hypothesis that cell-cycle control architectures obey the HOT paradigm. Three cell-cycle
models were analyzed using monte-carlo sensitivity analysis. Overall state sensitivity coefficients, which quantify the
robustness or fragility of a given mechanism, were calculated using a monte-carlo strategy with three different numerical
techniques along with multiple parameter perturbation strategies to control for possible numerical and sampling artifacts.
Approximately 65% of the mechanisms in the G1/S restriction point were responsible for 95% of the sensitivity, conversely,
the G2-DNA damage checkpoint showed a much stronger dependence on a few mechanisms; ,32% or 13 of 40
mechanisms accounted for 95% of the sensitivity. Our analysis predicted that CDC25 and cyclin E mechanisms were strongly
implicated in G1/S malfunctions, while fragility in the G2/M checkpoint was predicted to be associated with the regulation
of the cyclin B-CDK1 complex. Analysis of a third model containing both G1/S and G2/M checkpoint logic, predicted in
addition to mechanisms already mentioned, that translation and programmed proteolysis were also key fragile subsystems.
Comparison of the predicted fragile mechanisms with literature and current preclinical and clinical trials suggested a strong
correlation between efficacy and fragility. Thus, when taken together, these results support the working hypothesis that
cell-cycle control architectures are HOT networks and establish the mathematical estimation and subsequent therapeutic
exploitation of fragile mechanisms as a novel strategy for anti-cancer lead generation.
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Introduction
The capability to gather protein-protein and protein-DNA
interaction data, for example using the Yeast Two-Hybrid (Y2H)
system [1,2], Fluorescence Resonance Energy Transfer (FRET)
techniques [3], quantitative Mass Spectrometry (MS) proteomic or
Chromatin Immunoprecipitation (ChIP)-DNA micro-array tech-
niques [4,5] has far outstripped our ability to understand it.
Transforming large-scale interaction data into a better under-
standing of the biomolecular networks underlying disease
progression and eventually to new therapies requires integrative
tools and strategies. Perhaps one strategy to leverage our
knowledge of interaction networks into efficacious therapies would
be to identify and exploit weak or fragile mechanisms while
avoiding the manipulation of robust network interactions.
Robustness, a long-recognized property of living systems and
networks, allows function in the face of uncertainty while fragility,
i.e., extreme sensitivity, can potentially lead to catastrophic failure
following seemingly innocuous perturbations [6–10]. Different
factors can influence why elements of a network are robust or
fragile. Venkatasubramanian and co-workers demonstrated that
the structure of complex networks can result from a trade-off
between efficiency and robustness [11] while You and Yin
explored how the environment has shaped the robust properties
of bacteriophage T7 [12]. Leibler computationally predicted and
later experimentally verified robust features of chemotaxis control
networks [13] and Stelling et al., reviewed several examples of
robust biological networks [9]. Perhaps no better example of
robustness can be found than cell division. The cell-cycle is one of
the most fundamental and highly controlled processes in biology.
The decision to divide is tightly regulated integrating extracellular
signals, such as growth factors and hormones, with intracellular
cues that coordinate events leading to division. However, despite
extensive control and surveillance subsystems guiding the
progression of cells through the division cycle, malfunctions do
occur as evidenced by the uncontrolled proliferation underlying
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programmed cells to be robust to shifting nutritional environments
or varying growth factor availability, perhaps rare challenges could
result in unforeseen consequences. For example, exposure to
radiation, exotic chemicals (carcinogens) or even Single Nucleotide
Polymorphisms (SNPs) may cause seemingly innocuous changes
which manifest themselves in the breakdown of cell-cycle logic.
Carlson and Doyle have hypothesized that highly-evolved
networks can be resistant to some perturbations while extremely
sensitive to others. The ‘‘robust yet fragile’’ duality of networks
and systems has been termed Highly Optimized Tolerance (HOT)
and has been the basis of new lines of inquiry in computational
and experimental biology [10].
Sensitivity analysis is an enabling tool for the investigation of
robustness and fragility in networks relevant to human health and
more generally for model-based knowledge discovery. Cho et al.,
used sensitivity analysis to study TNF-a-mediated NF-kb signaling
where parametric uncertainty was addressed using a monte-carlo
parameter sampling protocol; a family of random parameter sets,
generated from the best parameter guess, was used to calculate the
sensitivity profile in a region of parameter space [15]. Bullinger
and coworkers explored the robustness of models of programmed
cell death or apoptosis [16] while Stelling et al., computationally
identified points of robustness and fragility, using monte-carlo
sensitivity analysis and Overall State Sensitivity Coefficients
(OSSCs), in models of circadian rhythm [17]. Mahdavi et al.,
employed sensitivity analysis to better understand stem cell
differentiation [18], while Luan et al., used an uncertain
mechanistic model of the coagulation cascade in combination
with monte-carlo sensitivity analysis, to show that computationally
derived sensitive mechanisms were consistent with anticoagulation
therapeutic strategies [19]. Sensitivity analysis has also been used
to integrate model identification and discrimination with optimal
experimental design. Several optimal experimental design and
model identification studies are resident in the literature [20–24]
along with many techniques to estimate sensitivity coefficients for
models composed of ordinary differential equations, differential
algebraic and stochastic equations [25–28].
In this study, we employ mathematical modeling and monte-
carlo sensitivity analysis to explore the working hypothesis that
cell-cycle control architectures are HOT networks. If our working
hypothesis is true, then fragile cell-cycle mechanisms (reaction
steps) should be overrepresented among experimentally observed
malfunctions underlying solid and hematological cancers. More-
over, the manipulation of fragile mechanisms in a therapeutic
context, which has been suggested by Kitano [29] to be more
likely to elicit an efficacious response from a network or system,
should also be prevalent in the treatment literature. We test our
working hypothesis by computationally screening three overlap-
ping qualitative models of cell-cycle control architectures; we
employ monte-carlo sensitivity analysis and k-means clustering to
rank-order mechanisms in cell-cycle and then contrast the
predicted fragile and robust mechanisms with literature. If cell-
cycle control architectures obey the HOT paradigm, then
computational identification of fragile mechanisms using protein-
protein or protein-DNA network models could be a novel strategy
for anti-cancer lead generation or more broadly as a strategy to
identify and exploit weakness in arbitrary networks relevant to
human health.
Results
The whole-cycle model of Novak and Tyson (Fig. 1), the G1-S
model of Qu et al., (Fig. 2A) and the G2/M-DNA damage model
of Aguda (Fig. 2B) were implemented from literature and screened
for fragile mechanisms using monte-carlo sensitivity analysis [30–
32]. The Novak and Tyson model, which employed a complex
description of the G1/S and G2/M checkpoints, programmed
protein expression and degradation, was composed of 18 dynamic
species, 4 species constraints and 74 parameters. The mass-action
G1/S and G2/M-DNA damage models described only the
molecular logic in their respective checkpoints; the G1/S model
was composed of 16 dynamic protein balances, 2 species
constraints and 44 parameters while the G2/M-DNA damage
model consisted of 15 dynamic protein balances,1 constraint and
40 parameters. Parameter values for each model were taken from
literature. Unreported initial conditions were adjusted so that
simulated model trajectories were qualitatively consistent with
published values (Supplementary Material Figure S1). The
published parameter sets, with fixed initial conditions, were used
to generate random parameter sets (N=500, unless otherwise
noted) where each nominal parameter was perturbed by up to
650%, 61-order, or 62-orders of magnitude. Overall State
Sensitivity Coefficients (OSSCs) were calculated over the random
parameter families for each cell-cycle model using three different
numerical algorithms. For each model, the mean OSSC values
were ranked-ordered and plotted. The Area Under the Curve
(AUC) was used to measure the cumulative sensitivity contribution
of each parameter. A cumulative cutoff of 95% of the overall
sensitivity was used to establish the list of mechanisms (Supple-
mentary Material Figure S2) which were clustered into three
groups (high, medium and low sensitivity) using a k-means
algorithm.
Approximately 65% of the G1/S mechanisms (reaction steps)
were responsible for 95% of the sensitivity, conversely, the G2-
DNA damage network showed a stronger dependence on a few
interactions. Of the 44 G1/S reactions steps, 29 were responsible
for 95% of the sensitivity (Supplementary Material Figure S2). The
distribution of fragility was not specific to any single class of
interaction (Table 1). The dephosphorylation of CDC25, the
expression of cyclin E, the degradation of the cyclin E-CDK2
complex, and the concentration of the transcription factor E2F
were classified as the most fragile reaction steps in the G1/S
checkpoint (Table 1, cluster I). A previous model of G1/S by
Aguda et al., [33] found that although pRB and cyclin E-CDK2
formed a positive feedback loop, they did not form a sharp robust
switch at the restriction point, i.e., the increase in active cyclin E-
CDK2 concentration was gradual and sensitive to model
parameters. However, addition of CDC25 to the positive cyclin
E-CDK2-pRB feedback loop, made the restriction point robust to
model parameter variation, thus supporting our findings of the
importance of CDC25 interactions. The synthesis, activation and
degradation of CKIs, the expression and degradation of CDC25,
pRB concentration, the expression of cyclin D and cyclin E-CDK2
mechanisms dominated the second-tier of G1/S fragility (Table 1,
cluster II). Tier-three of G1/S fragility involved several cyclin D
mechanisms, cyclin E-CDK2 activity and E2F mediated cyclin E
expression (Table 1, cluster III). When taken together, the most
heavily implicated G1/S protein was cyclin E, with 11 of 29
mechanisms, followed by CKIs with six, CDC25 and cyclin D
were each involved in five fragile mechanisms and E2F and pRB
were each listed twice. Moreover, 16 of the 29 fragile parameters
were functionally associated with cyclin E and cyclin E-CDK2
activity. As expected, the expression and degradation of the G1/S-
phase cyclins and their associated CKIs were predicted to be
important. However, the expression and degradation of cyclin E
and other it’s interactions were ranked higher than the
corresponding cyclin D mechanisms with the exception of the
Fragility of the Cell-Cycle
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damage network showed a stronger dependence on a few
mechanisms when compared with G1/S; ,32% or 13 of 40
mechanisms accounted for 95% of the sensitivity (Supplementary
Material Figure S2). Consistent with G1/S, no single class of
mechanism dominated the fragility list. The most sensitive
mechanisms were related to the generation and degradation of
the cyclin B-CDK1 complex otherwise known as the Maturation
Promoting Factor (MPF) (Table 2). The top five mechanisms were
either directly or closely associated with the formation and activity
of MPF while mechanisms leading the deactivation of MPF, e.g.,
the expression, degradation and activity of p21, 14-3-3s and
Wee1 phosphorylation dominated the remaining eight mecha-
nisms (Table 2, cluster III). Activation of inactive MPF complex,
whose expression is negatively regulated by p53, was the most
sensitive G2 mechanism (Table 2, cluster I), followed by preMPF
generation, activation and transport of CDC25 into the nucleus
(Table 2, cluster II). The finding that all CDC25 related
mechanisms were more fragile than Wee1, is consistent with
earlier work by Aguda [34] which showed that even though both
Wee1 and CDC25 form a phosphorylation-dephosphorylation
(PD) loop with MPF, only CDC25 coupling gave rise to
qualitatively different behavior. Interestingly, while the generation
of p53 itself was not predicted to be sensitive, interactions
involving p53 were prevalent, e.g., the expression of inactive MPF
and p21, both of which are regulated by p53, were predicted to be
sensitive. Approximately 77% of the Novak and Tyson parameters
(57 of 74) were responsible for 95% of the sensitivity (Supplemen-
tary Material Figure S2). Both global and local components of the
model were predicted to be fragile. The most sensitive global
mechanism was the translational efficiency while local mechanisms
such as activation of IE (hypothetical protein which activates the
E3-ligase CDC20), expression of cyclin B and CDH1 degradation
were also predicted to be fragile (Table 3, cluster I). The second-
tier mechanisms were associated with deregulation of programmed
proteolysis (Table 3, cluster II). Interestingly, while the percentage
Figure 1. Schematic of the molecular logic of the whole-cycle model of Novak and Tyson [32] used in this study. The Novak and Tyson
model, composed of 18 dynamic species, 4 species constraints and 74 parameters, describes both the G1/S and G2/M checkpoints and programmed
protein expression and degradation. Nomenclature: Cdk1-Cyclin Dependent Kinase 1, Cdk2 - Cyclin Dependent Kinase 2, Cdk4/6 - Cyclin
Dependent Kinase 4 or 6, CycD - Cyclin D, CycB - Cyclin B, CycE - Cyclin E, CycA - Cyclin A, GF - Growth Factor, ERG - Early Response Genes, DRG -
Delayed Response Gene, E2F – Transcription Factor E2F, pRB - Retinoblastoma protein, p27 – A Cyclin Dependent Kinase Inhibitor (CKI), also called
Kip1, PPI - type1 protein phosphatase, IE - ‘‘Intermediary Enzyme’’, PPX-A phosphatase inactivating IE , APC - Anaphase Promoting Complex, a
family of E3 ligases, Cdh1 - an activator of APC class of ligases, Cdc20 - an activator of APC, Small red circle with P represents a phosphate group, a
(+) sign implies positive regulation whereas a (2) sign represents negative regulation.
doi:10.1371/journal.pone.0002016.g001
Fragility of the Cell-Cycle
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and Tyson model was the largest of the three models, several
mechanisms in cluster III had small OSSC values, including most
of the G1/S checkpoint logic. Thus, sampling the complex Novak
and Tyson model produced less information than the mechanistic
mass-action based G1/S and G2-DNA damage models.
The qualitative conclusions drawn from sampling the cell-cycle
models were robust to the choice of solution method and the size
of the parameter perturbation but sensitive to the number of
parameter sets sampled. Three different numerical techniques
were used to solve the sensitivity equations to control for possible
numerical artifacts. The ODE15s routine of Matlab (The Math-
works, Natick MA), a third-order backward-difference implicit
method (BDF3; see Supplementary Material S1) and forward finite
difference (FD), generated qualitatively similar sensitivity results
(Fig. 3). The lowest Spearman rank between any two methods
(ODE15s versus FD for the G1/S model) was 0.91 indicating a
worse case correlation of approximately 91%. Interestingly, while
the Spearman rank indicated good agreement between the
solution methods, there were statistically significant shifts in
OSSC values indicating the solution methods systematically
shifted mechanisms, i.e., different OSSC values were calculated
but the order or ranking of mechanisms was maintained (see
Supplemental Material Table S1). Two additional sampling
controls were conducted to verify the robustness of the qualitative
conclusions drawn from our analysis. First, the perturbation size
used to generate the random parameter families was varied to test
if different conclusions would have been drawn with different
perturbation sizes; OSSC values computed over random param-
eter families generated using 650%, 61-order and 62-orders of
magnitude showed no qualitative difference as quantified by the
Spearman rank correlation for the G1/S model (Fig. 4). The worst
case correlation of 0.90 was observed between the 650% and 62-
orders of magnitude cases indicating on average 90% of the
Figure 2. Schematic of the molecular logic of the G1/S (A) and G2/M (B) checkpoint models used in this study. The G1/S model of Qu et
al., is composed of 16 dynamic protein balances, 2 species constraints and 44 parameters [31]. TheG2-DNA damage model of Aguda is composed of
15 dynamic protein balances 1constraint and 40 parameters (30). Both the G1/S and G2/M models employ mass action kinetics and the parameters
are linear in the mass balances. Nomenclature G1/S: CDC25A - Dual Specificity Phosphatase CDC25A, Cdk2 - Cyclin Dependent Kinase 2, Cdk4/
6 - Cyclin Dependent Kinase 4 or 6, CycE - Cyclin E, CycD - Cyclin D, E2F - Transcription Factor E2F, pRB - Retinoblastoma protein, p27 - A Cyclin
Dependent Kinase Inhibitor (CKI), also called Kip1. Nomenclature G2/M: pMPF - pre-Maturation Promoting Factor, a complex of CycB (Cyclin B)
and Cdk1 (Cyclin Dependent Kinase1) in inactive form, MPF – active form of MPF, aCDC25 - active CDC25 phosphatase, iCDC25 – inactive form of
CDC25, aCDC25(P-216) – active CDC25, phosphorylated at Serine 216 residue, iCDC25(P-216) - inactive CDC25, phosphorylated at Serine 216, 14-
3-3s - 14-3-3s protein. In both the schematics, small red circles with P represent phosphate group, a (+) sign implies positive regulation whereas a
(2) sign represents negative regulation.
doi:10.1371/journal.pone.0002016.g002
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Such a strong correlation in Spearman ranks across 2-orders of
magnitude in the parameter values might suggest that network
structure (connectivity) is more important than parameter values.
Comparison of exactly similar mechanisms across the three models
supported the hypothesis of connectivity dominance where
mechanisms classified as either fragile or robust in the G1/S
and G2-DNA damage models were also predicted to be important
in the Novak and Tyson model, albeit with different ranks
(Table 4). There were 11 mechanisms which appeared exactly in
each model, 10 mechanisms were classified similarly while one was
ranked inconsistently. Second, the cumulative Spearman rank
correlation between sensitivity results generated using the
ODE15s, BDF3 and FD methods for each model was calculated
as a function of the number of parameter sets sampled. While the
cumulative Spearman rank converged to the population mean as
the number of parameter sets increased, a population size
dependence was observed (Fig. 5). For each model, the results
reported were obtained in the region of convergence; hence, no
new information would have been gained if additional random
parameter sets were sampled.
Discussion
Literature evidence supports the hypothesis that computation-
ally identified fragile cell-cycle interactions represent efficacious
targets. Consider the fragility of CDC25 mechanisms. Boutros et
al., recently reviewed the role of CDC25 phosphatases and
CDC25 inhibitors in human cancer progression and treatment
[35]. While the inhibition of CDC25 as a cancer treatment
strategy is still in the laboratory stage, several CDC25 inhibitors in
development have shown promising results. The CDC25 inhibitor
PM20 inhibited growth in human hepatoma-derived Hep3B cell-
lines at a inhibitory concentration (IC) .700 nM, PM-20 also
inhibited the growth of several other cell-lines, albeit at higher ICs
[36]. BN82685, which inhibited CDC 25A, B and C in-vitro and in-
Table 1. Comparison of Overall State Sensitivity Coefficients (OSSC) calculated for the G1/S model of Qu et al., [31].
OSSC-BDF OSSC-FD OSSC-ODE15s
Reaction Cluster m6sm 6sm 6s
Dephosphorylation of aCDC25 I 0.625260.2980 0.631460.2667 0.694260.2518
Degradation of aCycE-Cdk2 I 0.585460.3452 0.637360.3403 0.675660.3423
Concentration of E2F I 0.571060.3247 0.674460.3062 0.646960.2958
Synthesis of CycE I 0.458360.3364 0.513160.3476 0.606360.3502
Generation of aCKIs II 0.451360.2577 0.529760.2540 0.549460.2320
Concentration of pRb II 0.442960.2982 0.522460.2827 0.523860.2725
Phosphorylation of iCDC25 II 0.444260.3245 0.434960.2905 0.480360.2856
Synthesis of iCDC25 II 0.395260.1934 0.453560.2015 0.480160.1690
Synthesis of CycD II 0.336760.2230 0.398460.2340 0.437660.2411
Formation of iCycE-Cdk2 II 0.359060.2275 0.405360.2656 0.427160.2417
Dephosphorylation of iCKIs II 0.384160.2557 0.410160.2428 0.427160.2361
Degradation of iCDC25 II 0.319860.2129 0.371160.2436 0.378960.2239
Formation of CycE-Cdk2-CKI II 0.341060.1997 0.365560.2106 0.370660.1731
Dissociation of CycE-Cdk2 complex II 0.302360.2626 0.334360.2946 0.342860.3002
Degradation of CycE II 0.267160.2791 0.316360.3165 0.325060.3262
Phosphorylation of aCKIs II 0.290960.2459 0.270560.2017 0.318260.2099
Degradation of CKIs II 0.267860.2556 0.298560.2803 0.292160.2618
Formation of CycD-Cdk4/6 III 0.198760.1312 0.232560.1410 0.263960.1485
Dissociation of CycE-Cdk2-CKI III 0.262360.2512 0.264760.2722 0.258560.2563
Degradation of CycD III 0.186760.1654 0.219460.1786 0.257560.1910
iCycE-Cdk2RaCycE-Cdk2 III 0.209660.2617 0.247260.3047 0.232260.2888
Phosphorylation of CDC25 by aCycE-Cdk2 III 0.205760.2446 0.235860.2828 0.231860.2893
Formation of CycD-Cdk4/6-CKI III 0.180160.1130 0.205460.1164 0.226860.1232
Rate constant for pRb dephosphorylation III 0.394560.3126 0.201660.1152 0.226060.1164
Degradation of iCKI III 0.167860.1646 0.164460.1642 0.207760.1815
E2F dependent CycE expression III 0.221960.2849 0.243260.3064 0.206460.3020
Dissociation of CycD-Cdk4/6-CKI III 0.186760.1654 0.199360.1443 0.204660.1376
aCycE-Cdk2 regulated pRb phosphorylation III 0.155160.1055 0.181260.1122 0.200860.1127
Rate constant for CKI phosphorylation III 0.163860.2232 0.199860.2602 0.191160.2547
Three different numerical methods were used to solve the sensitivity equations; OSSC-BDF: 3rd order fixed step-size backward difference method (implicit); OSSC-FD:
forward-finite difference (explicit); and OSSC-ODE15s: 5th order variable step-size backward difference routine (implicit) from the Matlab (The Mathworks, Natick MA)
ODE suite. Each member of the nominal parameter set was randomly perturbed by up to 61-order of magnitude to form a family of random parameter sets (N=500).
OSSC were calculated for every member of the family of random parameter sets. The mean (m) 61-standard deviation (s) are reported.
doi:10.1371/journal.pone.0002016.t001
Fragility of the Cell-Cycle
PLoS ONE | www.plosone.org 5 April 2008 | Volume 3 | Issue 4 | e2016vivo and repressed the growth of HeLa and human pancreatic
tumor Mia PaCa-2 xenografts in athymic nude mice, also
inhibited the growth of human cell lines resistant to cytotoxic
drugs e.g., the human myeloblastic leukemia cell-line HL-60 [37].
The CDC25 antagonist, CPD-5, inhibited the growth of the rat
hepatoma cell-line JM-1 in-vitro and the mouse cancer cell-line
tsFT210 through selective inhibition of CDC25 [38]. Thus,
inhibition of CDC25 represents a viable treatment option which
could be pursued further in the clinic. Inhibition and degradation
of the active cyclin E-CDK2 complex, the second ranked
mechanism in the G1/S network, has also been exploited as a
treatment strategy. Bristol-Myers Squibb (BMS) developed BMS-
387032, a cyclin E-CDK2 inhibitor, with an IC50 of 95 nM [39].
Preclinical and phase I ovarian cancer studies demonstrated that
BMS-387032 possessed better efficacy than Flavopiridol, a
promiscuous CDK inhibitor [40]. Flavopiridol, the first cyclin
dependent kinase inhibitor in clinical trials, alone or in
combination with other drugs is currently being investigated in
52 active phase I or II trials [41]. Flavopiridol has been proposed
for the treatment of recurrent, locally advanced, or metastatic soft
tissue sarcoma [42], lymphoma and multiple myeloma [43],
metastatic breast cancer (with Trastumuzumab) [44] or in
combination with other drugs (Cisplatin and Carboplatin) for
the treatment of advanced solid tumors [45]. Cyclin E expression,
the fourth ranked mechanism in the G1/S model, has also been
explored therapeutically for the treatment of pancreatic and lung
cancers [46,47]. The correlation between fragility and treatment
strategy was also found to hold for the G2/M-DNA damage
network. The activation of preMPF (cyclin B–CDK1 complex),
catalyzed by CDC25, was predicted to be the most sensitive
mechanism in the G2/M-DNA damage model while three of the
four tier-two G2/M-DNA mechanisms were associated with
CDC25 activity. Bryostatin-1, a protein kinase C (PKC) inhibitor
and antagonist of the cyclin B-CDK1 complex, has been explored
in the clinic for the treatment of multiple myeloma [48], relapsed
non-Hodgkin’s lymphoma and chronic lymphocytic leukemia
[49]. In preclinical models, Bryostatin-1 has demonstrated single-
agent activity against B16 melanoma, M5076 reticulum sarcoma
and L10A B-cell lymphoma [50] and has been shown to disrupt
cyclin B-CDK1 complex formation and activity by several
different mechanisms [51,52]. When taken together, the top
fragile mechanisms for both the G1/S and G2/M phases of the
cell-cycle, estimated by monte-carlo sensitivity analysis, were
found to be consistent with on-going preclinical and clinical trials
for the treatment of a broad spectrum of human cancers.
Modulation of translational efficiency and the manipulation of
programmed proteolysis, prominently featured among the group
of fragile mechanisms across all the models, are also active areas of
therapeutic development. Initiation of translation in eukaryotes is
thought to be rate limiting [53] and overexpression of initiation
components, for example the initiation factor elF4E, occurs
frequently in human cancers [54]. Arnqvist and coworkers
explored translation inhibition in MCF-7 breast cancer cells
following cycloheximide, puromycin or emetine exposure in the
presence and absence of Insulin-like Growth Factor1 (IGF-1) [55].
Addition of puromycin, cycloheximide and emetine in the absence
of IGF-1 resulted in increased apoptosis at 48 hr relative to the
control, however, when IGF-1 was present, a concentration
dependent reduction in apoptosis was observed. Bjornsti and
Houghton recently reviewed another small molecule translation
inhibitor, Ramapycin [56], which inhibits the Target of Rama-
pycin (TOR) protein, a serine/threonine kinase involved in
translation and other functions. While Ramapycin has FDA
approval as an immunosuppressant, development of anticancer
therapies has been slow despite anti-tumor activity against
established solid-tumor models [57,58]. Ramapycin analogs have
been evaluated in clinical trials for the treatment of different
indications including pediatric patients with relapsed or refractory
acute leukemia and renal-cell carcinoma [56,59]. Peptide
inhibitors have also been used to downregulate translation e.g.,
BL22, an immunotoxin developed for the treatment of Chronic
Lymphocytic Leukemia (CLL) [60], consists of the variable FV
Table 2. Comparison of Overall State Sensitivity Coefficients (OSSC) for the G2-DNA damage model of Aguda [30].
OSSC-BDF OSSC-FD OSSC-ODE15s
Description Cluster m6sm 6sm 6s
pMPFRMPF, catalyzed by aCdc25 I 0.875960.1475 0.891060.1271 0.992460.0739
aCdc25RiCdc25 II 0.767660.1442 0.770360.1181 0.884560.0920
Generation of preMPF II 0.941360.1214 0.972060.0838 0.868460.1130
iCdc25cyto.RiCdc25nuc. II 0.927060.1164 0.941760.0938 0.835660.1014
iCdc25RaCdc25, catalyzed by MPF II 0.572860.2291 0.501060.1422 0.283560.1517
Generation of p21 III 0.486060.1784 0.503160.1949 0.283560.1517
Degradation of p21 III 0.483360.1760 0.485460.1838 0.281260.1481
p21+MPFRp212MPF III 0.338260.1406 0.341360.1504 0.201760.1248
p212MPFRp21+MPF III 0.335260.1373 0.325460.1438 0.197960.1172
Generation of 14-3-3s protein III 0.343460.1250 0.380260.1459 0.191360.1060
Degradation of 14-3-3s protein III 0.342160.1247 0.362560.1390 0.190960.1059
Wee1RWee1P, catalyzed by MPF III 0.321460.1338 0.327460.1489 0.173960.0878
Wee1PRWee1 III 0.307860.1306 0.299360.1381 0.166660.0855
Three different numerical methods were used to solve the sensitivity equations; OSSC-BDF: 3rd order fixed step-size backward difference method (implicit); OSSC-FD:
forward-finite difference (explicit); and OSSC-ODE15s: 5th order variable step-size backward difference routine (implicit) from the Matlab (The Mathworks, Natick MA)
ODE suite. Each member of the nominal parameter set was randomly perturbed by up to 61-order of magnitude to form a family of random parameter sets (N=500).
OSSC were calculated for every member of the family of random parameter sets. The mean (m) 61-standard deviation (s) are reported.
doi:10.1371/journal.pone.0002016.t002
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PLoS ONE | www.plosone.org 6 April 2008 | Volume 3 | Issue 4 | e2016Table 3. Comparison of Overall State Sensitivity Coefficients (OSSC) for the whole-cycle model of Novak and Tyson [32].
OSSC-BDF OSSC-FD OSSC-ODE15s
Description Cluster m6sm 6sm 6s
Translational efficiency (
‘
) I 0.790460.3264 0.864760.2372 0.665760.3816
Activation of ‘IE’ (k31) I 0.602660.3071 0.602660.3071 0.536160.3843
Generation of CycB (k1) I 0.565060.3015 0.499360.2299 0.500260.3471
Cdh1 degradation (k4) I 0.404360.2443 0.380560.2361 0.499760.3765
Degradation of ‘IEP’ (k32) II 0.495860.2863 0.357660.2219 0.475960.3417
Generation of Cdh1 (k93) II 0.443460.2863 0.357660.2219 0.475960.3417
CycA mediated degradation of Cdh1 (cA) II 0.443460.2934 0.302160.1895 0.448260.3853
Degradation of ‘PPX’(k34) II 0.226660.1621 0.278860.1995 0.283560.2604
Generation of dephosphatase PPX (k33) III 0.222460.1652 0.215260.1616 0.257260.2240
Activation of Cdc20 (k13) III 0.244160.3096 0.255760.2616 0.220260.2782
CycE dependent CycE:Kip1 dissociation (k8) III 0.046360.0798 0.004160.0058 0.198960.2545
CycE:Kip1 dissociation giving Kip1 (k98) III 0.046360.0798 0.010560.0635 0.198860.2545
CycE dependent Kip1 accumulation (yE) III 0.043860.0744 0.007860.0371 0.186160.2386
Cdh1 dependent degradation of Cyc B (k92) III 0.114360.1189 0.086560.1405 0.175960.1690
Generation of Cyc B (k01) III 0.148660.0760 0.133360.0672 0.175160.1649
Degradation of Cdc20 (k14) III 0.240260.2678 0.189860.2238 0.169260.2057
Total E2F (E2FT) III 0.146060.1282 0.424960.2385 0.152460.1424
Degradation of DRGs (k18) III 0.046360.1020 0.000360.0006 0.146160.1720
Expression of CycA, catalyzed by aE2F (k29) III 0.169760.1366 0.263960.1444 0.133460.1525
aE2F (k7) mediate CycE expression III 0.036760.0625 0.003560.0038 0.132560.1489
Formation of ‘GM’ (k27) III 0.091160.1014 0.127660.0863 0.130760.1474
Degradation of Cdc20 (J4) III 0.064960.0743 0.074360.1348 0.128160.1331
CycB dependent degradation of Cdh1 (cB) III 0.090260.1296 0.047860.0563 0.128160.1331
Synthesis of p27
Kip1 (k5) III 0.027260.0447 0.003260.0041 0.127460.1232
Synthesis of DRG products (k17) III 0.044260.0992 0.000360.0005 0.120560.1754
Maximum specific growth rate (m) III 0.123160.1431 0.172460.1096 0.117660.1490
CycE dependent decrease in Kip1 (k6) III 0.026460.0432 0.003060.0038 0.116160.1161
Decrease in E2F (k23) III 0.071360.0734 0.213860.2094 0.113060.1080
Degradation of Cdc20 (k12) III 0.068660.0969 0.030860.0419 0.109160.1041
Degradation of free E2F (aE2F (k22)) III 0.068360.0969 0.030860.0419 0.109160.1041
Total PP1T (PP1T) III 0.022060.0394 0.000160.0002 0.101160.1034
Synthesis of CycB (J1) III 0.057760.0356 0.059460.0378 0.099960.1341
Degradation of ‘GM’ (k28) III 0.084160.0957 0.102560.0688 0.096160.1092
CycE/A activation of PP1 (K21) III 0.020660.0370 0.000160.0002 0.094560.0972
Cdh1 dependent CycB degradation (k2) III 0.070660.0676 0.054760.0447 0.091160.1137
CycD dependent E2F:Rb dissociation (k20) III 0.022460.0402 0.002260.0208 0.087860.0941
CycE dependent activation of PP1 (wE) III 0.018360.0324 0.001160.0104 0.086560.0911
Degradation of ‘IEP’ (J32) III 0.046760.0551 0.031360.0428 0.085360.0774
Degradation of CycD and CycD:Kip1 (k10) III 0.017460.0307 0.000260.0004 0.085260.0889
GF dependent synthesis of CycD (k9) III 0.017160.0304 0.001260.0104 0.080560.0874
Degradation of ERG (k16) III 0.012960.0227 7.194610
2761.728610
26 0.080260.0912
Total pRb concentration (RbT) III 0.017960.0321 0.006860.0530 0.078060.0817
PP1 dependent pRb activation (k19) III 0.017960.0321 0.000160.0002 0.077260.0807
CycB dependent Cdc20 formation (k11) III 0.013860.0230 0.002360.0171 0.077060.0826
Formation of Cdh1 (J3) III 0.015360.0224 0.011860.0136 0.071060.1542
Formation of CycE-Cdk2-Kip1 (k25) III 0.014260.0246 0.000460.0006 0.069560.0687
Cdc20 dependent CycB degradation (k02) III 0.069760.1035 0.048960.0944 0.068560.1210
Formation of ERGs (k15) III 0.012460.0222 8.593610
2762.233610
26 0.066260.0759
DRG dependent formation of ERG(J15) III 0.020860.0399 4.998610
2768.465610
27 0.064960.0997
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peptide PE38. The second group of fragile mechanisms predicted
in Novak and Tyson and more generally across the G1/S and G2/
M-DNA damage networks involved deregulation of programmed
protein degradation. Programmed proteolysis via the Ubiquitin
Proteasome System (UPS), a critical component driving cell-cycle
progression [61], has been the target of several different
therapeutic developments [62]. The ubiquination of target
proteins involves the coordinated activity of the ubiquitin
activating enzyme family (E1), the ubiquitin-conjugating enzyme
family (E2) and the ubiquitin ligase family (E3) [63]. While E1
malfunctions have not been observed in cancer, deregulation of E3
and to a lesser extent E2 activity has been directly linked to cancer
progression [63]. The Novak and Tyson model has only a skeleton
representation of UPS, however, it does explicitly represent Cell
Division Cycle protein 20 (CDC20), CDH1 and Anaphase
Promoting Complex/Cyclosome (APC/C), all of which are E3
components. APC/C is the core subunit to which the adapter
proteins CDC20 and CDH1 bind [64–66]. Inhibition of specific
E3 ligases remains a technical challenge [67], however, cis-
imidazoline analogs called Nutlins have been developed which
inhibit MDM2, an E3-ligase responsible for the recognition of
p53. Activity of Nutlins-3 against a human osteosarcoma xenograft
model in nude mice showed 90% inhibition of tumor growth
relative to control [68].
While multiple lines of experimental evidence support the
assertion that malfunctions in fragile mechanisms are implicated in
solid and hematological cancers, some evidence is contradictory.
CDC25 activity, cyclin E expression and activity of cyclin E-
CDK2 were the largest group of fragile G1/S mechanisms.
Traditionally, cyclin E expression and cyclin E-CDK2 activity
were thought to be critical for cell-cycle progression [69]. Ohtsubo
et al., have shown that cyclin E-CDK2 activity was maximum
during the G1/S phase and overexpression of cyclin E accelerated
cell-cycle progression [70]. Lucas et al., showed that abnormal
cyclin E but not Cyclin D1 expression was able to override G1
arrest by the INK4a family of CKIs [71]. Keyomarsi et al., found
that cyclin E expression plays a strong role in human breast cancer
tumors and the cyclin E-CDK2 complex remains active
throughout the cell-cycle suggesting the now established hypoth-
esis that truncated (deregulated) cyclin E variants were responsible
for the constitutive function of cyclin E-CDK2 in breast cancer
tumors [72,73]. Recent studies, however, have challenged the
traditional role of cyclin E. Deletion of both cyclin E genes was
lethal in-utero but deletion of cyclin E1 or cyclin E2 was tolerated
with no obvious abnormalities [74]. Interestingly, double cyclin E
knockout mice were born alive if cyclin E was restored in the
embryonic component of the placenta [74] and CDK2 null mice
were born viable and healthy [75]. Thus, while the cyclin E and
CDK2 knockout studies seem to contradict the essential role of
cyclin E, clinical evidence suggests further studies are required.
Evidence supporting the involvement of other fragile components,
such as the concentration of E2F and pRB (constraints in the G1/
S and Novak and Tyson models), is also prevalent in the literature
[76,77]. However, contradictory evidence suggests that the role of
cyclin D mechanisms maybe complex. Sensitivity analysis
suggested that cyclin D-CDK4/6 and cyclin D-CDK4/6-CKIs
trimer mechanisms were robust or only moderately sensitive while
cyclin D expression was fragile in the G1/S checkpoint. While
Keenan et al., demonstrated in IIC9 Chinese hamster embryonic
fibroblasts that cyclin E expression renders cyclin D-CDK4
dispensable [78], overexpression of cyclin D variants, particularly
cyclin D1, has been observed in several human cancers [79,80].
Moreover, cyclin D1, D2 or D3
2/2 mice displayed tissue specific
phenotypes including defective proliferation [81–83]. However,
while mice lacking all the cyclin D genes died by day E17.5 of
gestation, most tissue and organs were formed by day E13.5
indicating that cyclin D was not required for embryogenies [84].
When taken together, the retrospective cyclin E studies in breast
cancer patients and the CDC25 studies support the hypothesis that
malfunctions in fragile mechanisms are strongly implicated in
cancer progression. However, the cyclin E and CDK2 knockout
studies as well the confusing role of cyclin D suggests a more
nuanced perspective in which redundant proteins or subsystems
might be able to compensate for malfunctions in fragile
mechanisms.
Consistent with the conjecture of Kitano, the anecdotal
comparison between predicted fragile mechanisms and literature
suggested that cell-cycle control architectures are HOT networks
[29]. However, while different controls were conducted to ensure
the fidelity of the monte-carlo sampling protocol, the mathemat-
ical models being explored were coarse-grained and not
structurally complete. While quantifying the impact of structural
uncertainty remains a critical challenge, the general correlation
OSSC-BDF OSSC-FD OSSC-ODE15s
Description Cluster m6sm 6sm 6s
CycB dissociation of CKI complex(gB) III 0.017060.0328 0.000360.0004 0.059860.0787
CycD-Cdk4/6-Kip1 association(k24) III 0.011060.0199 0.000260.0004 0.046960.0563
CycE dissociation of CKI complex(gE) III 0.009960.0134 0.002160.0022 0.046160.0510
Cdh20 depdendent Cdh1 formation (k3) III 0.073260.1007 0.060760.1165 0.043960.0851
CycE dependent pRb phosphorylation (lE) III 0.009860.0173 7.812610
2561.044610
24 0.041360.0467
Cyclin dependent pRb phosphorylation (k26) III 0.011260.0199 0.000160.0002 0.038360.0470
CycB dependent pRb phosphorylation (lB) III 0.012360.0238 5.447610
2561.567610
24 0.033360.0515
Cdc20 dependent CycA degradation (k30) III 0.018260.0289 0.013860.0184 0.032960.0458
Three different numerical methods were used to solve the sensitivity equations; OSSC-BDF: 3rd order fixed step-size backward difference method (implicit); OSSC-FD:
forward-finite difference (explicit); and OSSC-ODE15s: 5th order variable step-size backward difference routine (implicit) from the Matlab (The Mathworks, Natick MA)
ODE suite. Each member of the nominal parameter set was randomly perturbed by up to 61-order of magnitude to form a family of random parameter sets (N=150).
OSSC were calculated for every member of the family of random parameter sets. The mean (m) 61-standard deviation (s) are reported.
doi:10.1371/journal.pone.0002016.t003
Table 3. cont.
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other studies have yielded similar results [19]. Moreover, initial
results presented here suggest that while the quantitative values of
sensitivity coefficients calculated using different models with
overlapping biology will change between models, the qualitative
conclusions drawn may be invariant. However, this conclusion is
likely true only for a subset of mechanisms. One possible strategy
to explore structural uncertainty would be to construct detailed
subsystem models of the coarse-grained components which were
determined by our analysis to be fragile, e.g., translation or UPS.
While this top-down strategy does not specifically address
structural uncertainty, it does allow us to determine the molecular
interactions which are perhaps mediating fragility in the coarse-
grained model. A second critical issue is the choice of sensitivity
metric. OSSCs quantify the overall impact that a parameter has;
however, other measures of sensitivity might be better suited for
analysis of the cell-cycle. Doyle and colleagues have established
tools for the analysis of mammalian circadian rhythm that could
prove useful in understanding how fragility influences phenotypic
properties such as division frequency [17,85,86]. A third critical
issue not addressed in this study was safety. Highly efficacious
strategies have resulted in unwanted and possible harmful side
effects, e.g., the association of rofecoxib with adverse cardiovas-
cular events [87]. While there may not be an obvious linkage
between fragility and safety for single agents, initial retrospective
studies by Luan et al., using combinations of coagulation inhibitors,
have suggested that shifts in mechanism rank could be used to
understand molecular drug-drug synergies [19].
Figure 3. Sensitivity analysis results as a function of model and numerical method. Scaled Overall State Sensitivity Coefficients (OSSC)
were calculated for each cell-cycle model over a family of random parameters sets (N=500 unless otherwise noted) generated by randomly
perturbing the published set by 61-order of magnitude. Three different numerical methods were used to solve the sensitivity equations to control
for numerical artifacts. A–C: Sensitivity results for the Novak and Tyson model [32]. D–F: Sensitivity results for the G1/S checkpoint model of Qu et al.,
[31]. G–I: Sensitivity results for the G2/M-DNA damage model of Aguda [30]. The different numerical techniques used to solve the sensitivity
equations yield qualitatively similar results as quantified by the Spearman rank correlation between any two methods (lower right-hand corner of
each plot).
doi:10.1371/journal.pone.0002016.g003
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Model formulation and sensitivity analysis
The cell-cycle models used in this study [30–32] were
represented as systems of Differential Algebraic Equations (DAEs):
f x,p ðÞ {H
dx
dt
~0x t0 ðÞ ~x0 ð1Þ
where xMR
m denotes the concentration vector, f(x, p)MR
m denotes the
mass balance equation vector describing the kinetics and connec-
tivity of the cell cycle network and pMR
p denotes the parameter
vector. The diagonal m6m matrix H contains 1’s for dynamic
elements of the concentration vector, 0 otherwise (constraints).
The fragile elements of the cell-cycle networks were determined
by computing Overall State Sensitivity Coefficients (OSSC) [17].
OSSC values were calculated by first calculating the first-order
sensitivity coefficients (at time tk):
sij tk ðÞ ~
Lxi
Lpj
       
tk
ð2Þ
which are solutions of the equation:
H
dsj
dt
~A t ðÞ sjzbj t ðÞ j~1,2,...,P ð3Þ
subject to the initial condition sj(t0)=0. The quantity j denotes the
parameter index, P denotes the number of parameters and sj
denotes the m61 vector of first-order sensitivity coefficients with
respect to parameter j. The Jacobian matrix (A) and the matrix of
first derivatives of the mass balances w.r.t the parameter values (B)
(whose columns are denoted by bj) are given by:
A~
Lf
Lx
       
x ,p  ðÞ
B~
Lf
Lp
       
x ,p  ðÞ
ð4Þ
where x denotes a point along the nominal or unperturbed system
solution. We solved the sensitivity equations for each parameter
using three different numerical methods to control for possible
artifacts; a 3-order Backward Difference (BDF3) method was
compared with forward Finite Difference (FD), and the fifth-order
variable step-size ODE15s routine of Matlab (The Mathworks,
Natick MA). The matrices A and B were estimated numerically at
each time step using a generalized gradient algorithm [88].
Overall State Sensitivity Coefficients (OSSC), first used by Stelling
et al., to characterize mechanisms in circadian rhythm as fragile or
robust [18], were calculated for each parameter j:
Soj t ðÞ ~
p 
j
Ns
X NT
k~1
X Ns
i~1
1
x 
i
Lxi
Lpi
       
tk
"# 2 0
@
1
A
1=2
ð5Þ
The quantity NT denotes the number of time points used in the
simulation while Ns denotes the number of proteins/protein
complexes in the model. To account for parametric uncertainty,
the OSSC values (Soj) were calculated over a family of random
Table 4. Comparison of OSSC ranks for common mechanisms
in the G1/S, G2-DNA damage and Novak and Tyson models.
Mechanism
G1/S
(%)
G2/M
(%)
Whole-cell
model (%)
Generation of preMPF - 93628 0 618
Total concentrations
Total E2F concentration 93615 - 77610
Total pRb concentration 86615 - 43616
Reactions of CKIs
Generation of CKIs 86610 85626 8 612
CycE-Cdk2 associating with CKI 7069- 3 8 615
Dissociation of CycE-Cdk2-CKI 57619 - (8623,5 619)
CycD-Cdk4/6 associating with CKI 4868- 3 1 619
Dissociation of CycD-Cdk4/6-CKI 39611 - (47614, 8623,
4619)
Generation and Degradation
Degradation of CycE 66624 - 38615
Degradation of CycD 55615 - 47614
CycE generation catalyzed by E2F 41626 - 73616
The mean percentage ranking, defined as the fractional distance from the
lowest ranked mechanism, 61-standard deviation is reported. The 95% cutoff
for mechanisms to be included in the fragile set was 34%, 68% and 23% for the
G1/S, G2-DNA damage and Novak and Tyson models, respectively.
doi:10.1371/journal.pone.0002016.t004
Figure 4. Effect of the parameter perturbation size on conclusions drawn from sensitivity analysis of the G1/S model. A family of
random parameter sets was constructed (N=150) from the nominal set, where each parameter was perturbed by upto 650%, 61-order or 62-orders
of magnitude. The ODE15s routine of Matlab (The Mathworks, Natick MA) was used to solve the sensitivity equations. A: Cumulative Spearman ranks
between parameters sets with 650% change and 61order change. B: Cumulative Spearman ranks between parameters sets with 61-and 62-orders
of magnitude change. C: Cumulative Spearman ranks between parameters sets with 650%-and 62-orders of magnitude change.
doi:10.1371/journal.pone.0002016.g004
Fragility of the Cell-Cycle
PLoS ONE | www.plosone.org 10 April 2008 | Volume 3 | Issue 4 | e2016Figure 5. Spearman rank correlation as a function of the number of random parameter sets sampled. The red-dashed line in all cases
denotes the cumulative Spearman Rank obtained by sampling all parameter sets for any two methods. A–B: Cumulative Spearman rank versus the
number of parameter sets sampled for the G1-S model using the BDF3 and ODE15s methods (A) and Finite Difference (FD) and ODE15s methods (B),
respectively. C–D: Cumulative Spearman rank versus the number of parameter sets sampled for the G2-M model using the BDF3 and ODE15s
methods (C) and Finite Difference (FD) and ODE15s methods (D), respectively. E–F: Cumulative Spearman rank versus the number of parameter sets
sampled for the whole-cycle model using the BDF3 and ODE15s methods (E) and Finite Difference (FD) and ODE15s methods (F), respectively. In all
models and numerical methods, the cumulative Spearman rank converges to population value, however, the rate of convergence, i.e., the number of
random sets required to be sampled, is different for each model and method.
doi:10.1371/journal.pone.0002016.g005
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by up to 61-order of magnitude then solved the sensitivity
balances for each family member. To control for perturbation
effects, two other random parameter families were also tested
(650% and 62-orders of magnitude, N=500).
Statistical and clustering analysis of OSSC values
Three different tests were performed to identify large statistically
significant shifts in the OSSC values. The OSSC values calculated
over the family of parameter sets were assumed to be normally
distributed. The statistical significance of shifts in OSSC values for
each algorithm relative to ODE15s (control) were determined by
performing a Welch t-test with the null hypothesis that the means
of the OSSC values were equal at a 1% significance level [89].
The list of significant OSSC values was further restricted to only
those shifts with a magnitude larger than a specified z-score (1.0)
away from the squared mean displacement over the significant
OSSC values. We defined the displacement of an OSSC value
relative to the control as:
dj,q~   S Sq
oj{  S Sc
oj
   2
, j~1,2,...,P ð6Þ
where S SC
oj denotes the mean OSSC value over the family of
parameter sets for parameter j in the control while S Sq
oj denotes the
same quantity for algorithm q. A significant shift in OSSC value
was accepted if:
dj,qwzsdqzmdq ð7Þ
where z denotes a desired z-score, sdq denotes the standard
deviation of the total displacement over all significant OSSC
values for the q
th numerical algorithm and mdq denotes the mean of
the significant displacements for algorithm q. Large statistically
significant shifts in OSSC values, while perhaps indicative of the
shifting importance of mechanisms, do not guarantee that
mechanisms are qualitatively different between the algorithms
considered (see Supplementary Material Table S1). The Spear-
man rank correlation denoted by r and defined as:
r~1{
6
P P
i~1d2
i
NN 2{1 ðÞ
ð8Þ
was used to measure the difference in qualitative ranking of
mechanisms between algorithms considered.The quantity di denotes
the difference in the ordinal rank of mechanismsbetween algorithms
or perturbation size, N denotes the number of pairs of values and P
denotes the number of parameters considered. The Spearman rank
is bounded by 21$r$1; a Spearman rank of one indicates that two
ranked lists are identical, a Spearman rank of negative one indicates
a perfect negative correlation, while a Spearman rank of zero
indicates that two ranked lists are uncorrelated.
The distributions of OSSC values obtained from monte-carlo
sampling were clustered using a k-means algorithm [90]. The
mean and standard deviation obtained from the monte-carlo
sensitivity analysis was used to estimate the underlying OSSC
distribution (N=500 points) where the OSSC values were
assumed to be normally distributed. One-hundred different
clustering attempts were run for each model to control for
clustering artifacts. The most probable configuration was reported.
Supporting Information
Material S1
Found at: doi:10.1371/journal.pone.0002016.s001 (1.07 MB
DOC)
Figure S1 Qualitative comparison of simulations results of the
model implementations used in this study. A–B: Free and bound
Cyclin E versus time for the reimplementation (A) and published
(B) the G1/S model of Qu et al., [31]. C–D: Concentration
profiles of the Wee1, MPF and active CDC25 proteins versus time
for the reimplementation (C) and published (D) G2/M DNA
damage model of Aguda [30]. E–F: Concentration profiles for the
Cdh1 protein and the Cdk1:CycB complex versus time for the
reimplementation (E) and published whole-cycle model of Novak
and Tyson [32]. In all cases the reimplemented models were
qualitatively consistent with published results.
Found at: doi:10.1371/journal.pone.0002016.s002 (1.95 MB EPS)
Figure S2 Cumulative Sensitivity as a function of parameter
rank. The cumulative sensitivity contribution of each parameter
was calculated by calculating the Area Under the Curve (AUC)
using the trapazoid rule. Mechanisms responsible for 95% of the
total sensitivity in each model were collected, clustered and
analyzed. Panel A shows the result for G1/S model, Panel B - G2/
DNA damage model and Panel C shows the plot for the whole cell
model.
Found at: doi:10.1371/journal.pone.0002016.s003 (0.33 MB EPS)
Table S1 Statistically significant shifts of Overall State Sensitiv-
ity Coefficients (OSSCs) between solution methods computed
using the Welch t-test. The mean and one standard deviation of
the OSSC score computed over the family of random parameter
sets is reported. Only shifts recorded with a p-value of 0.01 and z-
score of 1 are shown.
Found at: doi:10.1371/journal.pone.0002016.s004 (0.04 MB
DOC)
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